Treatment of Vulvovaginitis in a 76-Year-Old Woman
In a 76-year-old woman, the first critical step is determining whether this is infectious vulvovaginitis (candidiasis, bacterial vaginosis, or trichomoniasis) versus genitourinary syndrome of menopause (GSM), as treatment differs completely between these conditions.
Diagnostic Approach
The age of 76 makes GSM (formerly atrophic vaginitis) the most likely diagnosis, but infectious causes must be ruled out first 1. Key distinguishing features:
- GSM presents with: vaginal dryness, burning, dyspareunia, thin/pale vaginal mucosa, elevated vaginal pH (>5.0), and minimal discharge 2
- Infectious vaginitis presents with: increased discharge, odor (bacterial vaginosis), pruritus (candidiasis), or purulent discharge (trichomoniasis)
Obtain objective testing rather than treating empirically - either microscopy with wet mount/KOH or molecular PCR testing, as clinical diagnosis alone has poor accuracy (less than 50% of clinically diagnosed VVC cases are confirmed) 3.
Treatment Algorithm
If Infectious Cause Confirmed:
For Vulvovaginal Candidiasis:
- First-line: Oral fluconazole 150 mg single dose 3
- Alternative: Intravaginal azoles (miconazole 1200 mg suppository single dose, or terconazole 0.8% cream for 3 days) 3
- All regimens from the 2021 CDC guidelines are equally effective for uncomplicated VVC 3
For Bacterial Vaginosis:
- Standard metronidazole or clindamycin regimens 1
For Trichomoniasis:
- Metronidazole 500 mg twice daily for 7 days (not single dose in treatment failures) 1
If GSM/Atrophic Vaginitis Diagnosed:
The definitive treatment is local vaginal estrogen therapy 2, 4. This addresses the underlying pathophysiology of hypoestrogenism causing:
- Thinning vaginal epithelium
- Elevated vaginal pH
- Loss of lactobacilli
- Increased susceptibility to infections 2
Options include vaginal estrogen creams, tablets, or suppositories. Both local and systemic estrogen effectively mature vaginal epithelium, but local therapy minimizes systemic absorption 2.
Critical Pitfalls in This Age Group
Do not treat empirically for candidiasis without confirmation - GSM is far more common at age 76 and will not respond to antifungals 1, 4
Consider desquamative inflammatory vaginitis in the differential if purulent discharge with elevated pH but negative infectious workup 1, 4
GSM increases susceptibility to secondary infections - the elevated pH and altered flora predispose to urinary tract infections and can allow candidiasis or bacterial vaginosis to develop 2. If both GSM and infection are present, treat the infection first, then address the underlying GSM
Recurrent symptoms warrant re-evaluation - if symptoms persist after appropriate antimicrobial therapy, reconsider the diagnosis and evaluate for GSM, vulvodynia, or dermatologic conditions 1
Special Considerations for Elderly Patients
The vaginal microbiome changes significantly post-menopause with loss of estrogen, leading to loss of protective lactobacilli and pH elevation from 3.5-4.5 to >5.0 2. This makes GSM the primary consideration in any 76-year-old with vulvovaginal symptoms, and addressing this underlying condition may prevent recurrent infectious episodes.